What is the market price of sparsentan/sparsentan? Latest selling prices and medical insurance coverage in 2025

Sparsentan is a dual-action drug that acts primarily as an antagonist at endothelin receptors and angiotensin II receptors. Its primary indication is the treatment of primary immunoglobulin A nephropathy (IgAN), a type of renal tubular damage caused by an abnormality in the immune system. Sparsentan's research is also expanding into focal segmental glomerulosclerosis (FSGS), a disease that affects kidney function in which patients' kidney tubules are severely damaged. By modulating relevant signaling pathways, sparsentin can help slow the progression of these diseases, thereby improving patients' quality of life.

Regarding the price of sparsentan, as there is currently no original drug on the market in China, the specific selling price information is not clear. According to the current market situation, the drug has been on the market for a relatively short time overseas. Common specifications include 200mg*30 tablets and 400mg*30 tablets. According to the current exchange rate, in the European market, the price of each box may exceed 40,000 yuan, and the actual price is affected by exchange rate fluctuations. Patients should pay special attention to these changes when purchasing.

In addition to the original drug, generic drugs of Sparsentan are also sold in overseas markets. Their ingredients are basically the same as the original drug, providing patients with more choices. For example, a generic drug of 400mg*30 tablets produced by a pharmaceutical factory in Laos is priced at more than 3,000 yuan, which is undoubtedly a relatively acceptable choice for some patients with limited financial conditions. However, when purchasing generic drugs, patients must carefully check the source and quality of the drugs to ensure safety and effectiveness.

In general, sparsentan shows good prospects in the treatment of primary immunoglobulinA nephropathy and focal segmental glomerulosclerosis. However, because it has not yet been launched in China, patients need to obtain it through overseas channels.

Reference materials:https://www.sparsentan.com/